|
Feb '17
|
Lord Arbuthnot of Edrom
|
|
Neuro-bio / NMS:NBIX |
£43.24
|
£158.29
|
266.07%
|
£256,251.13
|
|
Apr '16
|
Baroness Greenfield
|
|
Neuro-bio / NMS:NBIX |
£46.13
|
£158.29
|
243.14%
|
£240,197.25
|
|
Apr '24
|
Lord Balfe
|
|
Astrazeneca / LSE:AZN.L |
£12,024.00
|
£13,154.00
|
9.40%
|
£76,578.51
|
|
Dec '16
|
Lord Burns
|
|
Astrazeneca / LSE:AZN.L |
£4,116.00
|
£13,154.00
|
219.58%
|
£223,707.48
|
|
May '20
|
Lord Deighton
|
|
Astrazeneca / LSE:AZN.L |
£8,361.00
|
£11,236.00
|
34.39%
|
£94,070.09**
|
|
Mar '14
|
Viscount Eccles
|
|
Astrazeneca / LSE:AZN.L |
£3,876.50
|
£15,316.00
|
295.10%
|
£276,569.07**
|
|
Feb '21
|
Lord Etherton
|
|
Astrazeneca / LSE:AZN.L |
£7,422.00
|
£13,154.00
|
77.23%
|
£124,060.90
|
|
May '23
|
Lord Fink
|
|
Astrazeneca / LSE:AZN.L |
£11,774.00
|
£13,154.00
|
11.72%
|
£78,204.52
|
|
Sep '16
|
Lord Gadhia
|
|
Astrazeneca / LSE:AZN.L |
£5,099.00
|
£10,024.00
|
96.59%
|
£137,611.30**
|
|
Apr '12
|
Lord Glendonbrook
|
|
Astrazeneca / LSE:AZN.L |
£2,666.50
|
£13,154.00
|
393.31%
|
£345,314.08
|
|
May '24
|
Lord Goldsmith
|
|
Astrazeneca / LSE:AZN.L |
£12,156.00
|
£13,154.00
|
8.21%
|
£75,746.96
|
|
May '18
|
Lord Grabiner
|
|
Astrazeneca / LSE:AZN.L |
£5,417.00
|
£13,154.00
|
142.83%
|
£169,979.69
|
|
May '23
|
Lord Leitch
|
|
Astrazeneca / LSE:AZN.L |
£11,820.00
|
£12,340.00
|
4.40%
|
£73,079.53**
|
|
May '23
|
Lord Londesborough
|
|
Astrazeneca / LSE:AZN.L |
£11,924.00
|
£13,154.00
|
10.32%
|
£77,220.73
|
|
Nov '23
|
Lord Mance
|
|
Astrazeneca / LSE:AZN.L |
£10,230.00
|
£13,154.00
|
28.58%
|
£90,007.82
|
|
Jun '21
|
Lord Morse
|
|
Astrazeneca / LSE:AZN.L |
£8,005.00
|
£13,154.00
|
64.32%
|
£115,025.61
|
|
Apr '10
|
Baroness Noakes
|
|
Astrazeneca / LSE:AZN.L |
£2,938.00
|
£13,154.00
|
347.72%
|
£313,403.68
|
|
Dec '23
|
Lord Browne of Madingley
|
|
Allurion / NYQ:ALUR |
£3.31
|
£8.70
|
162.84%
|
£183,987.91
|
|
Dec '16
|
Lord Burns
|
|
Glaxosmithkline / NYQ:GSK |
£37.39
|
£50.67
|
35.52%
|
£94,862.26
|
|
Mar '14
|
Baroness Eccles of Moulton
|
|
Glaxosmithkline / NYQ:GSK |
£53.43
|
£56.69
|
6.10%
|
£74,271.01**
|
|
Apr '21
|
Lord Farmer
|
|
Glaxosmithkline / NYQ:GSK |
£36.65
|
£40.88
|
11.54%
|
£78,079.12**
|
|
Jan '20
|
Lord Gadhia
|
|
Glaxosmithkline / NYQ:GSK |
£46.50
|
£40.95
|
-11.94%
|
£61,645.16**
|
|
May '11
|
Lord Glendonbrook
|
|
Glaxosmithkline / NYQ:GSK |
£42.78
|
£50.67
|
18.44%
|
£82,910.24
|
|
Apr '10
|
Lord Levene of Portsoken
|
|
Glaxosmithkline / NYQ:GSK |
£39.38
|
£50.67
|
28.67%
|
£90,068.56
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Glaxosmithkline / NYQ:GSK |
£42.31
|
£50.67
|
19.76%
|
£83,831.24
|
|
Apr '10
|
Baroness Noakes
|
|
Glaxosmithkline / NYQ:GSK |
£39.49
|
£50.67
|
28.31%
|
£89,817.67
|
|
Jan '13
|
Lord Sassoon
|
|
Glaxosmithkline / NYQ:GSK |
£44.75
|
£50.67
|
13.23%
|
£79,260.33
|
|
Oct '20
|
Lord Taverne
|
|
Glaxosmithkline / NYQ:GSK |
£37.57
|
£40.95
|
9.00%
|
£76,297.58**
|
|
May '24
|
Lord Balfe
|
|
Glaxosmithkline / NYQ:GSK |
£44.02
|
£50.67
|
15.11%
|
£80,574.74
|
|
May '25
|
Lord Hayward
|
|
Glaxosmithkline / NYQ:GSK |
£37.37
|
£50.67
|
35.59%
|
£94,913.03
|
|
Aug '14
|
Lord Carter of Coles
|
|
Johnson & Johnson / NYQ:JNJ |
£100.16
|
£161.55
|
61.29%
|
£112,904.35**
|
|
Apr '22
|
Lord Cromwell
|
|
Johnson & Johnson / NYQ:JNJ |
£179.90
|
£154.37
|
-14.19%
|
£60,066.15**
|
|
May '23
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£165.03
|
£228.39
|
38.39%
|
£96,875.11
|
|
Jul '16
|
Lord Lloyd-Webber
|
|
Johnson & Johnson / NYQ:JNJ |
£122.64
|
£228.39
|
86.23%
|
£130,359.59
|
|
Jan '13
|
Lord Sassoon
|
|
Johnson & Johnson / NYQ:JNJ |
£72.69
|
£228.39
|
214.20%
|
£219,938.09
|
|
Aug '17
|
Lord Sterling of Plaistow
|
|
Johnson & Johnson / NYQ:JNJ |
£133.45
|
£157.98
|
18.38%
|
£82,866.99**
|
|
Feb '11
|
Lord Wasserman
|
|
Johnson & Johnson / NYQ:JNJ |
£60.93
|
£228.39
|
274.84%
|
£262,387.99
|
|
Mar '25
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£161.72
|
£228.39
|
41.23%
|
£98,857.90
|
|
Aug '18
|
Lord Carter of Coles
|
|
Danaher / NYQ:DHR |
£90.94
|
£223.01
|
145.23%
|
£171,659.87**
|
|
Apr '22
|
Lord Cromwell
|
|
Danaher / NYQ:DHR |
£245.55
|
£201.40
|
-17.98%
|
£57,414.25**
|
|
Jul '16
|
Lord Glendonbrook
|
|
Danaher / NYQ:DHR |
£72.15
|
£177.17
|
145.54%
|
£171,880.36
|
|
Apr '22
|
Lord Grabiner
|
|
Danaher / NYQ:DHR |
£248.88
|
£198.61
|
-20.20%
|
£55,860.39**
|
|
Aug '17
|
Lord Sterling of Plaistow
|
|
Danaher / NYQ:DHR |
£71.88
|
£212.78
|
196.02%
|
£207,216.44**
|
|
Jul '18
|
Lord Carter of Coles
|
|
Essilor International / VIE:EI.VI |
£126.10
|
£316.70
|
151.15%
|
£175,804.93**
|
|
Aug '18
|
Lord Carter of Coles
|
|
Unitedhealth Group / NYQ:UNH |
£253.22
|
£400.96
|
58.34%
|
£110,841.16
|
|
Jan '23
|
Lord Goldsmith
|
|
Unitedhealth Group / NYQ:UNH |
£490.06
|
£379.86
|
-22.49%
|
£54,259.07**
|
|
Nov '23
|
Lord Mance
|
|
Unitedhealth Group / NYQ:UNH |
£537.83
|
£400.96
|
-25.45%
|
£52,186.00
|
|
Jan '18
|
Lord Sterling of Plaistow
|
|
Unitedhealth Group / NYQ:UNH |
£221.16
|
£380.64
|
72.11%
|
£120,477.48**
|
|
Mar '25
|
Lord Fink
|
|
Unitedhealth Group / NYQ:UNH |
£518.20
|
£400.96
|
-22.62%
|
£54,162.87
|
|
Apr '25
|
Lord Grabiner
|
|
Unitedhealth Group / NYQ:UNH |
£594.40
|
£400.96
|
-32.54%
|
£47,219.38
|
|
Oct '25
|
Lord Sterling of Plaistow
|
|
Unitedhealth Group / NYQ:UNH |
£361.15
|
£356.26
|
-1.35%
|
£69,052.20**
|
|
Feb '19
|
Lord Carter of Coles
|
|
Mettler Toledo / NYQ:MTD |
£672.49
|
£1,144.84
|
70.24%
|
£119,167.27
|
|
May '19
|
Lord Sterling of Plaistow
|
|
Mettler Toledo / NYQ:MTD |
£701.77
|
£1,481.07
|
111.05%
|
£147,733.44**
|
|
Sep '20
|
Lord Carter of Coles
|
|
Thermo Fisher Scientific / NYQ:TMO |
£418.14
|
£464.61
|
11.11%
|
£77,779.45
|
|
Apr '22
|
Lord Grabiner
|
|
Thermo Fisher Scientific / NYQ:TMO |
£570.94
|
£438.15
|
-23.26%
|
£53,719.30**
|
|
May '18
|
Lord Green of Hurstpierpoint
|
|
Thermo Fisher Scientific / NYQ:TMO |
£215.97
|
£423.55
|
96.12%
|
£137,280.64**
|
|
Nov '23
|
Lord Mance
|
|
Thermo Fisher Scientific / NYQ:TMO |
£459.24
|
£464.61
|
1.17%
|
£70,818.53
|
|
Aug '20
|
Lord Sterling of Plaistow
|
|
Thermo Fisher Scientific / NYQ:TMO |
£416.17
|
£403.13
|
-3.13%
|
£67,806.66**
|
|
Jan '25
|
Lord Sassoon
|
|
Thermo Fisher Scientific / NYQ:TMO |
£583.64
|
£464.61
|
-20.39%
|
£55,723.90
|
|
Aug '25
|
Lord Green of Hurstpierpoint
|
|
Thermo Fisher Scientific / NYQ:TMO |
£463.04
|
£464.61
|
0.34%
|
£70,237.34
|
|
Aug '25
|
Lord Sterling of Plaistow
|
|
Thermo Fisher Scientific / NYQ:TMO |
£477.41
|
£475.66
|
-0.37%
|
£69,743.41**
|
|
Sep '21
|
Lord Darzi of Denham
|
|
Oxford Nanopore / LSE:ONT.L |
£612.60
|
£114.60
|
-81.29%
|
£13,095.01
|
|
Apr '22
|
Lord Spencer of Alresford
|
|
Oxford Nanopore / LSE:ONT.L |
£320.00
|
£114.60
|
-64.19%
|
£25,068.75
|
|
Apr '21
|
Baroness Deech
|
|
Novo Nordisk As / NYQ:NVO |
£36.35
|
£43.19
|
18.82%
|
£83,171.94
|
|
Apr '24
|
Lord Grabiner
|
|
Novo Nordisk As / NYQ:NVO |
£127.46
|
£64.73
|
-49.22%
|
£35,549.19**
|
|
Nov '23
|
Lord Mance
|
|
Novo Nordisk As / NYQ:NVO |
£101.69
|
£43.19
|
-57.53%
|
£29,730.55
|
|
May '22
|
Lord Reay
|
|
Novo Nordisk As / NYQ:NVO |
£56.40
|
£140.80
|
149.67%
|
£174,767.27**
|
|
Nov '21
|
Lord Sherbourne of Didsbury
|
|
Novo Nordisk As / NYQ:NVO |
£56.71
|
£70.73
|
24.73%
|
£87,313.29**
|
|
Apr '24
|
Lord Willoughby de Broke
|
|
Novo Nordisk As / NYQ:NVO |
£122.75
|
£43.19
|
-64.81%
|
£24,629.73
|
|
May '24
|
Lord Londesborough
|
|
Novo Nordisk As / NYQ:NVO |
£134.66
|
£43.19
|
-67.93%
|
£22,451.36
|
|
Apr '21
|
Baroness Deech
|
|
Zoetis / NYQ:ZTS |
£168.10
|
£78.71
|
-53.18%
|
£32,776.32
|
|
Mar '25
|
Lord Fink
|
|
Zoetis / NYQ:ZTS |
£162.82
|
£78.71
|
-51.66%
|
£33,839.21
|
|
Apr '21
|
Baroness Deech
|
|
Novartis / NYQ:NVS |
£88.38
|
£147.08
|
66.42%
|
£116,492.42
|
|
Apr '17
|
Lord Donoughue
|
|
Novartis / NYQ:NVS |
£66.05
|
£147.08
|
122.69%
|
£155,879.66
|
|
May '11
|
Lord Glendonbrook
|
|
Novartis / NYQ:NVS |
£54.04
|
£147.08
|
172.16%
|
£190,513.84
|
|
Apr '23
|
Lord Grabiner
|
|
Novartis / NYQ:NVS |
£95.80
|
£107.52
|
12.23%
|
£78,563.67**
|
|
Oct '19
|
Lord Farmer
|
|
Centene / NYQ:CNC |
£44.09
|
£72.71
|
64.91%
|
£115,438.87**
|
|
May '23
|
Lord Fink
|
|
Healthcare Group / LSE:SPI.L |
£227.50
|
£216.00
|
-5.05%
|
£66,461.54
|
|
Jan '24
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£251.85
|
£321.70
|
27.73%
|
£89,414.34
|
|
Apr '21
|
Lord Grabiner
|
|
Roche / EBS:ROG.SW |
£309.65
|
£321.70
|
3.89%
|
£72,724.05
|
|
Apr '17
|
Lord Leigh of Hurley
|
|
Roche / EBS:ROG.SW |
£255.80
|
£321.70
|
25.76%
|
£88,033.62
|
|
Aug '20
|
Lord Reay
|
|
Roche / EBS:ROG.SW |
£315.05
|
£249.80
|
-20.71%
|
£55,502.30**
|
|
Feb '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£285.70
|
£272.40
|
-4.66%
|
£66,741.33**
|
|
Mar '25
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£303.00
|
£321.70
|
6.17%
|
£74,320.13
|
|
Nov '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£309.00
|
£321.70
|
4.11%
|
£72,877.03
|
|
May '11
|
Lord Glendonbrook
|
|
Abbott Laboratories / NYQ:ABT |
£25.27
|
£88.41
|
249.91%
|
£244,939.23
|
|
May '23
|
Lord Londesborough
|
|
Abbott Laboratories / NYQ:ABT |
£108.82
|
£88.41
|
-18.76%
|
£56,870.98
|
|
Jan '13
|
Lord Sassoon
|
|
Abbott Laboratories / NYQ:ABT |
£32.90
|
£88.41
|
168.72%
|
£188,106.38
|
|
May '11
|
Lord Glendonbrook
|
|
Mesoblast / NMS:MESO |
£101.20
|
£14.37
|
-85.80%
|
£9,939.72
|
|
May '11
|
Lord Glendonbrook
|
|
Pfizer / NYQ:PFE |
£19.54
|
£25.21
|
28.99%
|
£90,290.96
|
|
Feb '16
|
Lord Lloyd-Webber
|
|
Pfizer / NYQ:PFE |
£29.02
|
£25.21
|
-13.14%
|
£60,803.98
|
|
May '11
|
Lord Glendonbrook
|
|
Smith & Nephew / NYQ:SNN |
£22.61
|
£30.08
|
33.07%
|
£93,147.36
|
|
Apr '10
|
Baroness Noakes
|
|
Smith & Nephew / NYQ:SNN |
£20.98
|
£30.08
|
43.37%
|
£100,360.37
|
|
Jan '13
|
Lord Glendonbrook
|
|
Waters / NYQ:WAT |
£87.09
|
£355.44
|
308.13%
|
£285,690.68
|
|
Oct '13
|
Lord Glendonbrook
|
|
Stryker / NYQ:SYK |
£69.42
|
£307.80
|
343.39%
|
£310,371.65
|
|
Nov '23
|
Lord Mance
|
|
Stryker / NYQ:SYK |
£275.00
|
£307.80
|
11.93%
|
£78,349.09
|
|
Mar '14
|
Lord Glendonbrook
|
|
Bb Biotech / EBS:BION.SW |
£33.36
|
£27.20
|
-18.47%
|
£57,074.34**
|
|
Jun '16
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£47.80
|
£44.20
|
-7.53%
|
£64,728.04
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£54.95
|
£44.20
|
-19.56%
|
£56,305.73
|
|
Oct '20
|
Lord Glendonbrook
|
|
Bds / NGM:BDSX |
£12.81
|
£16.81
|
31.23%
|
£91,857.92
|
|
May '15
|
Lord Glendonbrook
|
|
Medtronic / NYQ:MDT |
£78.41
|
£86.77
|
10.66%
|
£77,463.33**
|
|
Dec '25
|
Lord Sassoon
|
|
Medtronic / NYQ:MDT |
£100.77
|
£79.34
|
-21.27%
|
£55,113.62
|
|
Jan '18
|
Lord Glendonbrook
|
|
Cvs Health / NYQ:CVS |
£79.44
|
£98.32
|
23.77%
|
£86,636.45
|
|
Feb '13
|
Lord Nash
|
|
Cvs Health / NYQ:CVS |
£52.66
|
£77.90
|
47.93%
|
£103,551.08**
|
|
Jul '18
|
Lord Glendonbrook
|
|
Bayer / GER:BAYN.DE |
£95.26
|
£37.15
|
-61.00%
|
£27,298.97
|
|
Jun '19
|
Lord Glendonbrook
|
|
Alcon / NYQ:ALC |
£59.11
|
£80.92
|
36.90%
|
£95,828.11**
|
|
Dec '19
|
Lord Glendonbrook
|
|
Align Technology / NMS:ALGN |
£273.75
|
£182.08
|
-33.49%
|
£46,559.27
|
|
May '24
|
Lord Goldsmith
|
|
Abbvie / NYQ:ABBV |
£160.81
|
£216.49
|
34.62%
|
£94,237.30
|
|
Apr '21
|
Lord Grabiner
|
|
Boston Scientific / NYQ:BSX |
£39.32
|
£93.67
|
138.22%
|
£166,757.37**
|
|
Apr '22
|
Lord Grabiner
|
|
Intuitive Surgical / NMS:ISRG |
£277.85
|
£406.78
|
46.40%
|
£102,481.91
|
|
Jan '22
|
Lord Green of Hurstpierpoint
|
|
Intuitive Surgical / NMS:ISRG |
£284.18
|
£529.42
|
86.30%
|
£130,408.19**
|
|
Nov '21
|
Lord Sherbourne of Didsbury
|
|
Intuitive Surgical / NMS:ISRG |
£350.79
|
£406.78
|
15.96%
|
£81,172.78
|
|
Oct '25
|
Lord Carter of Coles
|
|
Intuitive Surgical / NMS:ISRG |
£551.30
|
£406.78
|
-26.21%
|
£51,649.92
|
|
Oct '15
|
Lord Hayward
|
|
Sage / NGM:SAGE |
£46.11
|
£8.68
|
-81.18%
|
£13,177.19
|
|
Dec '22
|
Lord Hintze
|
|
Atai Life Sciences / NGM:ATAI |
£3.48
|
£3.87
|
11.21%
|
£77,844.83**
|
|
Dec '22
|
Lord Hintze
|
|
Affimed / NGM:AFMD |
£21.20
|
£0.18
|
-99.14%
|
£599.29**
|
|
Mar '11
|
Lord Hollick
|
|
HCA / NYQ:HCA |
£31.02
|
£375.17
|
1,109.45%
|
£846,611.89
|
|
Nov '17
|
Lord Howard of Rising
|
|
Ekf Diagnostics / LSE:EKF.L |
£25.01
|
£26.80
|
7.16%
|
£75,009.39
|
|
Apr '22
|
Lord Hylton
|
|
Genus / LSE:GNS.L |
£2,678.00
|
£2,174.00
|
-18.82%
|
£56,825.99
|
|
Jan '24
|
Lord Kakkar
|
|
Cyte / NMS:CTKB |
£8.31
|
£3.71
|
-55.35%
|
£31,251.50**
|
|
Apr '10
|
Lord Lloyd-Webber
|
|
Idexx Labs / NMS:IDXX |
£29.96
|
£562.09
|
1,776.13%
|
£1,313,294.50
|
|
Aug '16
|
Lord Lloyd-Webber
|
|
Eli Lilly / NYQ:LLY |
£80.55
|
£67.15
|
-16.64%
|
£58,355.06**
|
|
Apr '24
|
Lord Mendoza
|
|
Eli Lilly / NYQ:LLY |
£731.33
|
£1,098.57
|
50.22%
|
£105,150.75
|
|
Apr '26
|
Lord Grabiner
|
|
Eli Lilly / NYQ:LLY |
£955.19
|
£1,098.57
|
15.01%
|
£80,507.43
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Hikma Pharmaceuticals / LSE:HIK.L |
£2,026.00
|
£1,451.00
|
-28.38%
|
£50,133.27
|
|
Sep '21
|
Lord Londesborough
|
|
Definitive Healthcare / NMS:DH |
£43.29
|
£0.76
|
-98.24%
|
£1,228.92
|
|
Jul '21
|
Lord Londesborough
|
|
Goodrx / NMS:GDRX |
£32.52
|
£4.79
|
-85.27%
|
£10,310.58**
|
|
Nov '23
|
Lord Mance
|
|
Eli Lilly Co / VIE:LLYC.VI |
£557.00
|
£951.70
|
70.86%
|
£119,603.23
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Candel Therapeutics / NGM:CADL |
£1.40
|
£8.31
|
493.57%
|
£415,500.02
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Journey Medical / NCM:DERM |
£3.74
|
£7.25
|
93.85%
|
£135,695.19**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Evotec / NMS:EVO |
£7.13
|
£3.41
|
-52.17%
|
£33,478.26**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Fortress Biotech / NCM:FBIO |
£1.92
|
£2.99
|
55.73%
|
£109,010.42
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Mustang Bio / NCM:MBIO |
£1.04
|
£0.65
|
-37.50%
|
£43,750.00
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Tg Therapeutics / NCM:TGTX |
£15.05
|
£53.22
|
253.62%
|
£247,534.89
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Adaptimmune / NMS:ADAP |
£1.47
|
£0.03
|
-98.28%
|
£1,207.14**
|
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Avenue Therapeutics / NCM:ATXI |
£12.00
|
£0.33
|
-97.29%
|
£1,899.04
|
|
Apr '19
|
Lord Nash
|
|
Eq / NCM:EQ |
£8.20
|
£0.69
|
-91.59%
|
£5,890.24**
|
|
Aug '23
|
Lord Nash
|
|
Relay / NGM:RLAY |
£10.62
|
£15.88
|
49.53%
|
£104,670.43
|
|
Sep '23
|
Lord Nash
|
|
Abingdon / LSE:ABDX.L |
£11.25
|
£11.50
|
2.22%
|
£71,555.56
|
|
Mar '24
|
Lord Petitgas
|
|
Royalty Pharma / NMS:RPRX |
£30.08
|
£52.96
|
76.06%
|
£123,244.68
|
|
Mar '24
|
Lord Petitgas
|
|
Moderna / NMS:MRNA |
£111.98
|
£63.96
|
-42.88%
|
£39,982.14
|
|
May '23
|
Lord Reay
|
|
Sanofi / NMS:SNY |
£55.11
|
£47.22
|
-14.32%
|
£59,978.23**
|
|
May '22
|
Lord Saatchi
|
|
Walgreen / NMS:WBA |
£43.85
|
£11.98
|
-72.68%
|
£19,124.29
|
|
Jul '23
|
Lord Sassoon
|
|
Haleon / LSE:HLN.L |
£336.10
|
£333.80
|
-0.68%
|
£69,520.97
|
|
Mar '23
|
Baroness Shields
|
|
Benevolentai / AMS:BAI.AS |
£2.46
|
£0.09
|
-96.14%
|
£2,703.25**
|
|
Jan '21
|
Lord Spencer of Alresford
|
|
Immupharma / LSE:IMM.L |
£12.65
|
£4.41
|
-65.18%
|
£24,375.50
|
|
May '23
|
Lord Sterling of Plaistow
|
|
Essilorluxottica / PAR:EL.PA |
£180.80
|
£204.10
|
12.89%
|
£79,023.12**
|
|
Jun '24
|
Lord Sterling of Plaistow
|
|
Essilorluxottica / PAR:EL.PA |
£208.20
|
£197.20
|
-5.28%
|
£66,301.63**
|
|
Aug '24
|
Lord Sterling of Plaistow
|
|
Essilorluxottica / PAR:EL.PA |
£207.50
|
£177.60
|
-14.41%
|
£59,913.26
|
|
Mar '25
|
Lord Fink
|
|
Essilorluxottica / PAR:EL.PA |
£273.20
|
£177.60
|
-34.99%
|
£45,505.12
|
|
Jun '22
|
Lord Stevens of Ludgate
|
|
Verici Dx / LSE:VRCI.L |
£26.00
|
£0.38
|
-98.56%
|
£1,009.62
|
|
May '23
|
Lord Stevens of Ludgate
|
|
Avacta Group / LSE:AVCT.L |
£112.00
|
£73.50
|
-34.38%
|
£45,937.50
|
|
Jul '25
|
Lord Fink
|
|
Avacta Group / LSE:AVCT.L |
£51.50
|
£73.50
|
42.72%
|
£99,902.91
|
|
Jun '22
|
Lord Sugar
|
|
Acl / NMS:ACLX |
£17.47
|
£115.07
|
558.67%
|
£461,070.43
|
|
May '22
|
Lord Triesman
|
|
Blue / NMS:BLUE |
£3.39
|
£4.97
|
46.61%
|
£102,625.36
|
|
May '20
|
Lord Wolfson of Aspley Guise
|
|
Adc Therapeutics / NYQ:ADCT |
£30.00
|
£1.09
|
-96.37%
|
£2,543.33
|
|
Nov '24
|
Lord Moynihan of Chelsea
|
|
Sab Biotherapeutics / NCM:SABS |
£3.95
|
£4.00
|
1.27%
|
£70,886.08
|